NASDAQ:TNXP News 16 August 2025

TNXP Stock Today, 7 December 2025: Price, Latest News and 2026 Forecasts for Tonix Pharmaceuticals

Tonix Pharmaceuticals (NASDAQ: TNXP) has quietly turned into one of 2025’s wildest biotech stories: a tiny company that finally won U.S. FDA approval for a fibromyalgia drug after a 15‑year drought, launched it in the U.S., expanded the same molecule

7 December 2025

Tonix Pharmaceuticals (TNXP) Stock Today, December 4, 2025: Tonmya Launch, Buyback and $400M ATM Define a Volatile Biotech Story

As Tonix Pharmaceuticals transitions from clinical-stage hopeful to commercial biotech on the back of its new fibromyalgia drug Tonmya, Wall Street is split between blockbuster dreams and dilution fears. TNXP Stock on December 4, 2025: Price, Volume and Volatility Tonix

4 December 2025

Biotech · Company News · Investments · NASDAQ:TNXP · Pharmaceuticals · Stock Market

TNXP Stock Today (Nov. 25, 2025): Tonix Slips as Wall Street Weighs MDD IND Win, Tonmya Launch, and Dilution Risk

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) had a busy news day on Monday — and the stock still finished sharply lower. Shares of the small-cap biotech closed around $14.29 on November 25, 2025, down roughly 11% on the session, putting

25 November 2025

Biotech News · Company Updates · Financial Analysis · Investing · NASDAQ:TNXP · Stock Market

Tonix Pharmaceuticals (TNXP) Jumps as TONMYA, First New Fibromyalgia Drug in 15 Years, Hits U.S. Pharmacies – November 17, 2025

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) moved sharply higher today after the company confirmed that TONMYA™ (cyclobenzaprine HCl sublingual tablets), its newly approved fibromyalgia treatment, is now commercially available by prescription across the United States. GlobeNewswire+1 TONMYA Officially Launches in

17 November 2025

Drug Approvals · Fibromyalgia · Healthcare News · Medical Innovations · NASDAQ:TNXP · Pharmaceuticals

Biotech, Pharma, and Health Breakthroughs You Missed on August 17–18, 2025

New Drug Approvals & Clinical Trial Results Mergers, Acquisitions & Partnerships (No other major M&A deals were announced during Aug 17–18, but this Lilly-Superluminal alliance highlights the continued investment in AI-driven R&D.) Regulatory & Policy Updates Public Health & Epidemiology

18 August 2025

Biotech · Health · Medical News · NASDAQ:GBT · NASDAQ:MDGL · NASDAQ:TNXP · NYSE:NVO · NYSE:PFE · Pharma · Research

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Wegovy (semaglutide) received FDA accelerated approval to treat metabolic dysfunction-associated steatohepatitis (MASH), becoming the first GLP-1 therapy cleared for MASH in a patient population estimated at about 5% of U.S. adults, based on part 1 of an ongoing trial showing

16 August 2025

Biotechnology · Health News · Medical Innovations · Mergers & Acquisitions · NASDAQ:BNTX · NASDAQ:CVAC · NASDAQ:TNXP · NYSE:LLY · NYSE:NVO · NYSE:PFE · Pharmaceuticals

NASDAQ:TNXP News 16 August 2025 - 7 December 2025